文献速递膀胱癌与上尿路尿路上皮癌

高级别尿路上皮癌中的分级异质性:对接受充分辅助卡介苗治疗的中/高危非肌层浸润性膀胱癌患者生存是否有影响?

Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guérin Therapy?
PubMed 文献 · J Urol · 2024-05-01

本回顾性队列研究纳入2010至2020年初始经尿道电切标本诊断为高级别非肌层浸润性膀胱癌的患者,比较纯高级别与混合级别患者的无复发生存和无进展生存。203例中69例(34%)为混合级别;两组36个月无复发生存率相似(P=.58),但纯高级别组36个月无进展生存率更差(P=.042)。多因素分析显示年龄和肿瘤分级是进展的显著危险因素。

要点

  • 203例中69例(34%)为混合级别肿瘤,纯高级别组134例。
  • 36个月无复发生存率纯高级别组69% vs 混合级别组72%,两组相似(P=.58)。
  • 36个月无进展生存率纯高级别组84% vs 混合级别组94%,纯高级别组更差(P=.042)。

核心结论

  • 病理报告中把混合级别尿路上皮癌与纯高级别癌分开报告似乎是一个重要问题,可指导患者管理,实现更准确的风险分类和患者咨询,并更准确地制定治疗方案。
  • 作者认为,为获得更精确的结论,本研究结果应得到更大样本量前瞻性研究的支持。

研究设计与样本

  • 回顾性队列分析,使用机构数据库数据。
  • 纳入2010年至2020年间初始经尿道电切标本诊断为高级别非肌层浸润性膀胱癌的患者。
  • 所有患者的初始经尿道电切标本均由专职泌尿病理学家重新评估,并确定每例中伴随高级别区域的低级别肿瘤区域百分比。
  • 采用Kaplan-Meier法进行时间至事件分析,比较两组间的无复发生存率和无进展生存率。

主要发现

  • 共纳入203例患者,其中69例(34%)为混合级别肿瘤。
  • 纯高级别组134例中41例(30.6%)出现复发,混合级别组69例中19例(27.5%)出现复发。
  • 36个月无复发生存率纯高级别尿路上皮癌组为69%(CI:62-77),混合级别尿路上皮癌组为72%(CI:62-83),两组相似(log-rank,P=.58)。
  • 纯高级别组134例中22例(16.4%)出现进展,混合级别组69例中4例(5.8%)出现进展。
  • 36个月无进展生存率纯高级别尿路上皮癌组为84%(CI:77-90),混合级别尿路上皮癌组为94%(CI:89-100),纯高级别组无进展生存率更差(log-rank,P=.042)。

临床怎么用

  • 作者认为,病理报告中把混合级别尿路上皮癌与纯高级别癌分开报告似乎是一个重要问题,可指导患者管理,实现更准确的风险分类和患者咨询,并更准确地制定治疗方案。

局限性

  • 作者指出,为获得更精确的结论,本研究结果应得到更大样本量前瞻性研究的支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to compare recurrence-free survival (RFS) and progression-free survival (PFS) of the patients with pure high-grade (HG) vs mixed-grade (MG) nonmuscle-invasive bladder cancer who received adequate bacillus Calmette-Guérin therapy. MATERIALS AND METHODS: We conducted a retrospective cohort analysis using data from an institutional database. The study included patients diagnosed with HG nonmuscle-invasive bladder cancer at the initial transurethral resection specimen between 2010 and 2020. The initial transurethral resection specimens of all patients were reevaluated by a dedicated uropathologist. The percentage of low-grade tumor areas accompanying HG areas was determined for each case. Time-to-event analysis was performed using the Kaplan-Meier method. RFS and PFS rates were compared between groups. RESULTS: Of the 203 patients enrolled in the study, 69 (34%) had MG tumors. Recurrence was observed in 41 out of 134 patients (30.6%) in the HG group and in 19 out of 69 patients (27.5%) in the MG group. The 36-month RFS rates were 69% (CI: 62-77) and 72% (CI: 62-83) for the HG-urothelial carcinoma (UC) and MG-UC groups, respectively. The RFS rates were similar between groups (log-rank, P = .58). Progression was observed in 22 out of 134 patients (16.4%) in the HG group and in 4 out of 69 patients (5.8%) in the MG group. The 36-month PFS rates were 84% (CI: 77-90) and 94% (CI: 89-100) for the HG-UC and MG-UC groups, respectively. The pure HG-UC group had a worse PFS than the MG-UC group (log-rank, P = .042). Multivariate analysis demonstrated that age and tumor grade were significant risk factors for the development of progression. CONCLUSIONS: The indication of MG-UC category separately from pure HG carcinomas in the pathology report seems to be an important issue that can guide patient management. In this way, both more accurate risk classification and more accurate patient counseling can be performed. More importantly, the treatment plan can be made more accurately. For more precise conclusions, our results should be supported by prospective studies with larger sample size.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Karaburun MC, Kuz ED, Akpınar Ç, et al. Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guérin Therapy? J Urol. 2024. PMID: 38690779. doi:10.1097/JU.0000000000003990

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。